Kronos Bio, Inc.: Revision history

20 August 2022

• curprev 06:0606:06, 20 August 2022 95.149.241.133 talk 896 bytes +11 No edit summary undo

13 August 2022

• curprev 07:4207:42, 13 August 2022 109.180.50.163 talk 885 bytes +15 No edit summary undo

29 July 2022

• curprev 22:4122:41, 29 July 2022 >Chris 870 bytes +870 Created page with "Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrationa..."